Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 25, Issue 10, Pages 2086-2090Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2019.06.012
Keywords
Access to transplantation; Health services research; Allogeneic transplantation
Categories
Funding
- Public Health Service [5U24CA076518]
- National Cancer Institute (NCI)
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases [1U24HL138660]
- NHLBI [HHSH250201700006C]
- Health Resources and Services Administration [N00014-17-1-2388, N00014-17-1-2850, N00014-18-1-2045]
- Office of Naval Research
- Adaptive Biotechnologies
- Match Foundation
- Gilead Sciences, Inc.
- HistoGenetics, Inc.
- Immucor
- Karyopharm Therapeutics, Inc.
- Medac
- Takeda Oncology Co.
- Novartis Pharmaceuticals Corporation
- St. Baldrick's Foundation
- University of Minnesota
Ask authors/readers for more resources
Allogeneic hematopoietic cell transplantation (alloHCT) is offered in a limited number of medical centers and is associated with significant direct and indirect costs. The degree to which social and geographic barriers reduce access to alloHCT is unknown. Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) were integrated to determine the rate of unrelated donor (URD) alloHCT for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) performed between 2000 and 2010 in the 612 counties covered by SEER. The total incidence of AML, ALL, and MDS was determined using SEER, and the number of alloHCTs performed in the same time period and geographic area were determined using the CIBMTR database. We then determined which sociodemographic attributes influenced the rate of alloHCT (rural/urban status, median family size, percentage of residents below the poverty line, and percentage of minority race). In the entire cohort, higher levels of poverty were associated with lower rates of alloHCT (estimated rate ratio [ERR], .86 for a 10% increase in the percentage of the population below the poverty line; P < .01), whereas rural location was not (ERR, .87; P= .11). Thus, patients from areas with higher poverty rates diagnosed with ALL AML, and MDS are less likely patients from wealthier counties to undergo URD alloHCT. There is need to better understand the reasons for this disparity and to encourage policy and advocacy efforts to improve access to medical care for all. (C) 2019 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available